GC Biopharma and Acuitas Therapeutics announced that they have entered into a Development and Option agreement for Acuitas' LNP technology. Under the terms of the agreement, GC Biopharma will obtain the option to license Acuitas' LNP technology for up to four undisclosed targets, on a non-exclusive basis, for vaccine or therapeutic development. GC Biopharma has selected mRNA as the new development platform and has been conducting related research since late 2017.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,14,400 KRW | -0.17% | +0.79% | -8.84% |
03/05 | Green Cross Widens Q1 Loss, Sales Inch Up 2% | MT |
20/03 | GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.84% | 955M | |
+29.98% | 682B | |
+30.34% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.21% | 240B | |
+9.66% | 209B | |
-6.83% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- A006280 Stock
- News GC Biopharma Corp.
- GC Biopharma Concludes Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics